Metabolic crisis and TRPM4 activation cause QT prolongation in TANGO2 deficiency disorder

Lili Wang1, Kyungsoo Kim1, Prince J Kannankeril2

  • 1Vanderbilt Center for Arrhythmia Research and Therapeutics, Division of Clinical Pharmacology, Vanderbilt University Medical Center, 2215B Garland Ave, Nashville, TN 37232-0575, USA.

Abstract

Insights

TANGO2 deficiency disorder causes cardiac issues due to impaired energy metabolism. TRPM4 channel activation, linked to ATP deficiency, drives action potential prolongation and arrhythmias in this condition.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Genetics

Background:

  • TANGO2 deficiency disorder (TDD) involves impaired fatty acid oxidation, leading to metabolic crises, QT prolongation, and arrhythmias.
  • The precise mechanisms underlying these cardiac complications in TDD remain incompletely understood.

Purpose of the Study:

  • To investigate the mechanisms responsible for QT prolongation and arrhythmogenesis in TANGO2 deficiency disorder.
  • To explore potential therapeutic targets for TDD-associated cardiac dysfunction.

Main Methods:

  • Generated TANGO2-deficient human induced pluripotent stem cell cardiomyocytes (hiPSC-CMs) using CRISPR/Cas9.
  • Assessed bioenergetic function and action potentials under varying substrate conditions (glucose vs. palmitate).
  • Investigated the role of L-type calcium channels (LTCCs) and TRPM4 channels in TDD cardiac phenotypes.

Main Results:

  • TANGO2-/- hiPSC-CMs exhibited impaired ATP production and reduced ATP/ADP ratios when fueled by palmitate, mimicking metabolic crisis.
  • Palmitate-induced crisis led to action potential prolongation, which was ameliorated by Mg-ATP, creatine kinase, or LTCC inhibition (verapamil).
  • Metabolic crisis upregulated TRPM4 channels, and TRPM4 inhibition prevented action potential prolongation without restoring bioenergetics.

Conclusions:

  • A mechanistic link exists between ATP deficiency, TRPM4 channel activation, and action potential prolongation in TDD.
  • TRPM4 channel activation contributes significantly to the arrhythmogenic phenotype in TDD.
  • Targeting TRPM4 presents a potential therapeutic strategy for preventing cardiac arrhythmias in TDD crises.

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Dysrhythmias II: Classification of Tachyarrhythmias01:28

Dysrhythmias II: Classification of Tachyarrhythmias

Tachyarrhythmias are a type of dysrhythmia where the heart rate exceeds 100 beats per minute. Here are some common types of tachyarrhythmias:Sinus TachycardiaSinus tachycardia originates from increased impulses from the sinus node, leading to an elevated heart rate. It is often triggered by stress, fever, or exercise.Patients may experience palpitations, a sensation of a racing heart, dizziness, and chest discomfort.Causes and Risk Factors: Common causes include physical exertion, emotional...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...